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The number of circulating lymphocytes on day 15 after transplantation correlates with improved survival in
patients with myeloma, but the lymphocyte subset responsible is unknown. NKG2D is a natural killer (NK)
cell activating receptor that mediates non-MHC restricted and TCR-independent cell lysis. Our preliminary
results indicate that CD3þCD8þ T cells expressing NKG2D may be a critical lymphocyte population. A phase II
trial examined the feasibility of infusing ex vivo-expanded cells enriched for NKG2DþCD3þCD8þ T cells at
weeks 1, 2, 4, and 8 after an autologous transplantation. In addition, low-dose IL-2 (6  105 IU/m2/day) was
administered for 4 weeks, beginning on the day of transplantation. Twenty-three patients were accrued and
19 patients are evaluable. There were no treatment-related deaths. All patients completed their course of IL-2
and demonstrated normal engraftment. When compared with patients with myeloma who underwent
transplantation not receiving posttransplantation immune therapy, the treated patients demonstrated an
increase in the number of circulating NKG2DþCD3þCD8þ T cells/mL (P < .004), CD3þCD8þ T cells/mL (P < .04),
CD3þCD8þCD56þ T cells/mL (P < .004), and NKG2DþCD3-CD56þ T cells/mL (P < .003). Myeloma cell-directed
cytotoxicity by the circulating mononuclear cells increased after transplantation (P < .002). When
compared to posttransplantation IL-2 therapy alone in this patient population, the addition of cells enriched
for NKG2DþCD3þCD8þ T cells increased tumor-speciﬁc immunity, as demonstrated by enhanced lysis of
autologous myeloma cells (P ¼ .02). We postulate that this regimen that increased the number and function
of the NKG2DþCD3þCD8þ T cells after transplantation may improve clinical outcomes by eliminating residual
malignant cells in vivo.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION We developed ex vivo expansion methods to enrich for
Multiple myeloma is incurable with standard therapy
[1,2]. The number of lymphocytes infused as part of the
transplanted graft and the number of lymphocytes circu-
lating on day 15 after transplantation, known as the “ALC15,”
correlate with improved progression-free and overall
survival [3,4]. Despite these results, the lymphocyte subset
responsible for the improved outcome is unknown. Our
preliminary results suggest that a subset of CD3þCD8þ T cells
that express a natural killer (NK) cell activating receptor,
called NKG2D, may be the responsible lymphocytes [5-10].
NKG2D is expressed on the cell surface of some CD8þ T cells,
NK cells and gdT cells. It mediates non-MHC restricted and
TCR-independent cell lysis by recognizing 1 of its 6 ligands
[11]. The NKG2D ligands are selectively expressed on tumor
cells, including myeloma, lymphoma, leukemia, and most
carcinomas [12,13].dgments on page 136.
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12.08.018NKG2DþCD3þCD8þ T cells using mobilized peripheral blood
progenitor cells [14]. These NKG2DþCD3þCD8þ T cells
recognized and killed autologous myeloma cells, and the
cytotoxicity correlated with the amount of ligand expression
on the tumor cell [5,6,8,14-16].
Based on these results, we designed a phase II clinical trial
to evaluate the efﬁcacy of infusing ex vivo-expanded cells
enriched for NKG2DþCD3þCD8þ T cells after an autologous
transplantation. Patients also received posttransplantation
IL-2 for 4 weeks [5,7,8,17,18]. The clinical objectives were to
deﬁne engraftment and toxicity in patients conditioned with
this regimen. The laboratory objective was to evaluate the
in vivo effects of this therapy. The results demonstrate
a signiﬁcant recovery of autologous myeloma-speciﬁc cyto-
toxic lymphocytes after transplantation, including an
increase in the number of circulating NKG2DþCD3þCD8þ
T cells/mL with increased autologous myeloma cell-directed
cytotoxicity.
MATERIALS AND METHODS
Patient Population and Eligibility Criteria
Patients between the ages of 17 and 70 years with pathologically
conﬁrmed multiple myeloma and a Karnofsky status of 80% were eligible
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Cyclophosphamide 
G-CSF
Leukocytopheresis
of  HPC
High-dose
melphalan
IL-2 for 4 weeks
Ex Vivo expansion & 
modification of  
effector cells
Cellular infusions at 4 
time points
Week
1         2                 4                   8
Day 0 
Transplant
Figure 1. Treatment schema. HPC indicates hematopoietic progenitor cells. IL-2 was administered weeks 1 through 4. Week 1 ¼ day #3 posttransplantation;
week 2 ¼ day #14 posttransplantation; week 4 ¼ day #28 posttransplantation; and week 8 ¼ day #56 posttransplantation.
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an ejection fraction 45%, carbon monoxide diffusing capacity 60%, and
forced expiratory volume in 1 second and forced vital capacity both70% of
predicted. The creatinine clearance was required to be >50 mL/min. The
protocol was approved by Dartmouth Medical School’s Committee for the
Protection of Human Subjects. All patients signed an informed consent to
participate in this study. Any patient who successfully mobilized and
received a transplantationwith IL-2 therapy was considered to be evaluable.
Treatment Plan
Mobilization
Peripheral blood progenitor cells were mobilized using cyclophospha-
mide (3 grams/m2). Recombinant granulocyte colony-stimulating factor
(Amgen, Thousand Oakes, CA) was started 48 hours after the cyclophos-
phamide and continued daily (10 mg/kg/day) until completion of cell
collection (Figure 1). Leukocytopheresis was initiated after recovery of the
WBC count to >1000/mL and the peripheral blood CD34þ cell number was
5 CD34þ cells/mL. Daily leukocytophereses of 15 to 20 liters of whole blood
(approximately 3.5 to 4.5 total blood volumes over the course of
300 minutes) were performed and continued until 3  106 CD34þ cells/kg
had been collected.
Transplantation regimen
Patients receivedmelphalan (200 mg/m2) on day -3 and progenitor cells
were infused on day 0. The goal was to infuse 3  106 CD34þcells/kg.
Prophylactic ciproﬂoxacin, penicillin, acyclovir, and ﬂuconazole were
administered beginning on the day of melphalan administration.
The dose and duration of IL-2 (Prometheus Laboratories Inc, San Diego,
CA) were based on our prior clinical trials [7,17-19]. IL-2 (6  105 IU/m2/day)
was started on day 0 and administered as a twice-a-day subcutaneous
injection, and given on a 5-days on 2-days off cycle for 4 consecutive weeks.
Granulocyte macrophage colony-stimulating factor (250 mg/m2/day) (Bayer,
Pittsburgh, PA) was started on day 5 and continued until the absolute
granulocyte count exceeded 1000/mL.
Ex vivo expansion methods
The ex vivo expansion was performed under good manufacturing
practice standards, using a Food and Drug Administration-approved IND
(IND #13205) [8]. Brieﬂy, at the time of progenitor cell collection, a portion
of the cells was used for ex vivo expansion. The cells that were used for the
transplantationwere cryopreserved in cryoprotectant containing 20% DMSO
(Cryoserv, Bioniche Pharma LLC, Lake Forest, IL), 40% autologous plasma, and
40% Normosol-R (Hospira Inc, Lake Forest, IL) that was mixed with the
patient’s cells in a 1:1 ratio (ﬁnal DMSO concentration was 10%). For the
expansion process, the remaining cells were processed on the Elutra Cell
Separation System (Caridian BCT, Lakewood, CO) to isolate and to enrich for
lymphocytes. The lymphocyte fraction was placed into 1000 mL Lifecell
Culture Bags (Baxter, Deerﬁeld, IL) with serum-free AIM V medium (Invi-
trogen Corp. Carlsbad, CA), IL-2 (1000 IU/mL) and OKT-3 (500 ng/mL) (Ortho
Biotech Products, Raritan, NJ). The IL-2, OKT-3, and supplemental AIM V
were added every other day and the cultures were incubated in 5% CO2 at
37C for 7 days. On day 7, a sample was evaluated for cell number, viability,
and CD3þ cell content. Cell expansionwas determined using ﬂow cytometry
by identifying the absolute number of CD3þ cells in culture. Release criteria
of the cells included a negative gram stain, negative endotoxin (Lonza, Basel,
Switzerland), and mycoplasma testing (Bionique Testing Laboratories, Sar-
anac Lake, NY). Each sample was also cultured for 7 days using Aerobic/
Anaerobic BacT/Alert culture (bioMerieux, Marcy l’Etoile, France).Ex vivo cell infusions
The expanded cells were infused during week #1 (day 3), week #2
(day 14), week #4 (day 28), and week #8 (day 56) (Figure 1). The goal was to
administer 1109 ex vivo expanded CD3þ Tcells at each of the 4 time points
[8,14,20-22]. Each patient whose cells expanded was to receive the ex vivo
expanded cells, if release criteria were met. Each patient was analyzed on an
“intent-to-treat” schema. To exploit the period of posttransplantation
immune reconstitution, ex vivo-expanded cells were to be infused begin-
ning within 3 days after transplantation. Cells were thawed in a hot water
bath at the patient’s bedside and infused i.v. over 30 minutes.
Posttransplantation monitoring
Patients were evaluated daily during their transplantation course by
physical examination, a complete blood count, electrolytes, and kidney and
liver function tests. Toxicities were graded according to the National Cancer
Institute Common Toxicity Criteria (version 4.0). All data were placed into
a bone marrow (BM) transplantation-speciﬁc database (Stem Soft Company,
Vancouver, British Columbia, Canada). Irradiated RBCs or single donor
platelet transfusions were administered if patients were symptomatic or if
the hemoglobin fell below 8 g/dL or the platelets dropped below 5000/mL,
respectively. Engraftment was deﬁned as an absolute neutrophil count
of 500/mL for 3 consecutive days and a platelet count of 20,000/mL for 3
consecutive days (untransfused).
Monitoring after discharge
After discharge, patients were evaluated weekly for 1 month and then
returned to their referring hematologist. Weekly visits included a physical
examination, a blood count, electrolytes, and kidney and liver function tests.
Patients were evaluated for response at day 100 posttransplantation,
then every 6 months for 2 years, and then annually. The evaluation included
a physical examination, BM aspirate and biopsy, skeletal survey, serum
protein electrophoresis, urine protein electrophoresis, and liver and kidney
function tests.
Deﬁnitions of response
Complete response (CR) required the disappearance of monoclonal
protein in serum and urine, and a BM biopsy demonstrating 5% plasma
cells. Skeletal x-rays were required to show either recalciﬁcation or no
change in lytic lesions. A very good partial response (VGPR) was deﬁned as
a CR, except for the presence of an isolated monoclonal M spike. Partial
response (PR) was deﬁned as >50% reduction in monoclonal protein in
serum and urine, a decrease in BM plasma cells by at least 25%, and no
increase in size or number of lytic lesions. Patients not meeting one of the
above categories were categorized as stable disease.Laboratory Analysis
Flow cytometry analyses
The cell surface phenotype of the circulating blood mononuclear cells
after transplantation was examined using ﬂow cytometry with
ﬂuorochrome-conjugated Abs directed against T lymphocytes (CD3, CD4,
CD8; BD Biosciences, San Jose, CA), NK cells (CD56; BD Biosciences), the
IL-2 receptor (CD25; BD Biosciences), and the NK cell activating receptor,
NKG2D (BD Biosciences). NKG2D ligand expression on patients’ myeloma
cells was measured by multicolor labeling of myeloma cells using Abs
directed against CD138 (a marker for myeloma cells, BD Biosciences),
MICA, MICB, ULBP1, ULBP2, and ULBP3 (1.25 mg/mL; R&D Systems,
Minneapolis, MN).
Table 1
Patient Demographics
Number of patients accrued n ¼ 23
Male/female 14/9
Age (median; range) 60 yrs (42-72 yrs)
Evaluable patients n ¼ 19
Nonevaluable patients n ¼ 4
Failed to mobilize cells n ¼ 2
Progressive disease n ¼ 1
Refused transplantation n ¼ 1
Type of myeloma
Ig G n ¼ 14 patients
Ig A n ¼ 1 patients
Ig M n ¼ 1 patients
Ig D n ¼ 1 patients
Light chain n ¼ 3 patients
Nonsecretory n ¼ 3 patients
Disease status at the time of transplantation
CR n ¼ 5 patients
VGPR n ¼ 8 patients
PR n ¼ 5 patients
Refractory n ¼ 1 patients
Number of previous therapies
One n ¼ 12 patients
Two n ¼ 7 patients
Three n ¼ 3 patients
Four n ¼ 1 patients
CR indicates complete response; VGPR, very good partial response; PR,
partial response.
K.R. Meehan et al. / Biol Blood Marrow Transplant 19 (2013) 129e137 131Cells were analyzed using FACScan or FACSCanto (Becton Dickinson, San
Jose, CA) using a standard lymphocyte gate and recorded as percent of
positive cells. Data were analyzed using Cell quest (Becton Dickinson, SanFigure 2. Patient accrual to trial. Demonstrates the patients’ accrual to tJose, CA) and FlowJo software (Tri star INC., Chatsworth, CA). The absolute
number of lymphocytes/ml was calculated by normalizing the percentage of
positive cells to each patient’s absolute number of circulating lymphocytes
on the corresponding day.
Isolation of myeloma cells from patients’ BM
Patients’ marrow samples were processed using Ficoll-Paque PLUS
density separation and then incubated in AIM V media supplemented with
IL-6 (R&D systems, Minneapolis, MN; 10 ng/mL) for 72 hours to enrich for
myeloma cells [10,23,24].
Cytotoxicity assays
A standard chromium release assay was performed to examine cyto-
toxicity of patients’ cells directed against myeloma cells [8,14]. A human
myeloma cell line (RPMI8226) or autologous myeloma cells served as
targets.Identiﬁcation of Control Patients for Comparison of Laboratory Results
We identiﬁed a control group of patients with myeloma (n ¼ 6) for
comparison of laboratory results. These patients withmyelomawere treated
during the same time period as the ongoing clinical trial. This control group
included patients with myeloma who received an autologous trans-
plantation after melphalan, at the same dose as the study patients. After
transplantation, the control patients received the same dose/duration of
growth factor support as the study patients. These patients did not receive
any immunotherapy.Statistical Analyses
The clinical objectives were to deﬁne engraftment and toxicity in
patients conditioned with this regimen. The laboratory objective was to
evaluate the in vivo effects of this therapy. The projected sample size
was estimated to be 19 evaluable patients. With this sample size, the
95% conﬁdence interval for engraftment will have a half-width not
exceeding 22%.he trial and distribution into evaluable and nonevaluable groups.
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were determined using the t test, at the 95% conﬁdence interval. Graph Pad
PRISM 5 statistical software (La Jolla, CA) or Microsoft Excel (Redmond, WA)
were used. Survival and duration of response were measured from the date
of transplantation.
RESULTS
Patient Demographics and Disease Characteristics
Twenty-three patients with myelomawere accrued to the
trial with a median age of 60 years (range, 42-72 years). Four
patients were not evaluable because of failure to mobilize
cells (n ¼ 2), progressive disease before mobilization (n ¼ 1),
or refusal to pursue transplantation (n ¼ 1). At the time of
transplantation, 5 patients were in CR, 8 patients demon-
strated a VGPR, and 5 patients were in PR. One patient had
refractory disease. The majority of patients received 1 prior
regimen (n ¼ 12; range, 1-4; Table 1).
Characteristics of the Ex Vivo-Expanded Cells
We demonstrated that the ex vivo expansion process
enriched for NKG2DþCD3þCD8þ T cells and that the CD8þ
T cells greatly increase NKG2D expression on their cell
surface during ex vivo expansion [14]. Ex vivo expansion
process resulted in a 3-fold increase in the number of CD3þ
T cells, equally distributed between CD3þCD4þ T cells (51%)
and CD3þCD8þ T cells (49%). A minor population within the
expanded cells included CD56þNK T cells, (CD8þCD56þ
T cells and CD3-CD56þ NK cells), comprising 6þ 0.6% of cells.
Viability of each of the ex vivo expanded products was>70%.
Mobilization, Ex Vivo Cell Expansion, and Infusion of Cells
Of the 19 evaluable patients who successfully mobilized
cells, the progenitor cells from 4 patients did not proliferate
(Figure 2). Of the remaining 15 patients, the goal was to
infuse 1  109 CD3þ T cells for each of the 4 infusions. The
number of infusions varied based on the number of cells that
expanded; patients received 4 infusions (n ¼ 9), 3 infusionsTable 2
Collection Products and Cell Numbers Infused
No. of Collections Cells Collected No. of CD
CD34/kg  106 MNC/kg  108 No.  106
UPN 1 1 16.2 1.07 9.23
UPN 2 NA NA NA NA
UPN 3 3 4.05 1.54 3.45
UPN 4 2 14 1.3 3.22
UPN 5 3 5.01 1.15 2.49
UPN 6 2 6.31 1.08 3.81
UPN 7 2 3.81 2.22 NA
UPN 8 3 9.33 2.12 4.04
UPN 9 2 15.7 1.45 4.68
UPN 10 2 10.1 1.75 5.29
UPN 11 2 10.1 3.89 6.47
UPN 12 2 12.7 2.93 3.12
UPN 13 3 2.89 5.86 1.84
UPN 14 2 2.77 7.78 NA
UPN 15 NA NA NA NA
UPN 16 2 3.66 5.04 3.74
UPN 17 2 12.1 3.09 NA
UPN 18 1 9.08 3.49 3.67
UPN 19 2 4.64 3.9 NA
UPN 20 NA NA NA NA
UPN 21 1 7.69 2.47 1.8
UPN 22 1 17.5 5.63 4.59
UPN 23 2 6.54 4.74 2.68
Median 2 7.69 2.47 3.7
Range (1-3) (2.77-17.5) (1.07-7.78) (1.84-9.23
MNC indicates mononuclear cell; NA, not applicable.(n ¼ 2), 2 infusions (n ¼ 2), or 1 infusion (n ¼ 2). The median
number of CD3þ T cells per infusionwas 1109 (range, 0.6
109 to 1.4  109).
Of the patients who demonstrated successful mobiliza-
tion and proceeded onto transplantation, the median
number of leukocytophereses was 2 (range, 1-3) with
a collection of 7.7  106 CD34þ cells/kg (median; range,
1-17.5  106) and 2.5  108 mononuclear cells/kg (median;
range, 1.1-7.8  108; Table 2). The median number of CD34þ
cells/kg infused was 3.7  106 cells CD34þ cells/kg (range,
1.8-9.2  106).Engraftment and Length of Stay
Of the 19 patients who underwent transplantation-
engrafted neutrophils on day 13 (median; range, 12-16
days) and platelets on day 16 (median; range, 10-26 days), 2
of the patients received their transplantation as an outpa-
tient and spent 3 days in the hospital (median; range, 2-4
days). The remaining 17 patients spent 17 days in the hospital
(median; range, 15-26 days).IL-2 Treatment, Posttransplantation Course, and
Toxicities
There were no treatment-related deaths. Each of the 19
evaluable patients completed the full course of IL-2 therapy.
The toxicities were relatively mild and transient. Four
patients experienced moderate (grade III, n ¼ 3) or severe
(grade IV, n ¼ 1) infections. Other moderate toxicities (grade
III) included nausea/vomiting (n ¼ 2), increased liver func-
tion tests (n ¼ 2), anorexia (n ¼ 3), mucositis (n ¼ 1), or
constipation (n ¼ 1).
Two patients experienced transient fever, tachycardia,
and hypotension (grade III toxicities) during the ex vivo cell
infusion. These signs and symptoms resolved within 1 hour
after the cell infusion.34/kg Infused No. of CD3þ T Cells Infused  109
Day 3 Day 14 Day 28 Day 56
9.23 NA NA NA
NA NA NA NA
1.13 NA NA NA
1.04 1.04 1.04 1.04
0.92 0.92 0.92 NA
0.62 0.62 0.62 0.62
NA NA NA NA
1.02 1.02 1.02 1.02
1.06 1.06 1.06 1.06
0.91 0.91 0.91 0.91
1.0 1.0 1.0 1.0
0.95 0.95 NA NA
0.63 0.63 NA NA
NA NA NA NA
NA NA NA NA
1.04 1.04 1.04 1.04
NA NA NA NA
NA NA NA NA
NA NA NA NA
NA NA NA NA
1.39 1.39 1.39 1.39
1.27 1.27 1.27 NA
1.0 1.0 1.0 1.0
1.01 1.01 1.01 1.01
) (0.62-1.39) (0.62-1.39) (0.62-1.39) (0.62-1.39)
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in the Peripheral Blood
Because our initial hypothesis was that this regimen
would increase the ALC15, we analyzed the absolute
lymphocyte recovery. Study patients demonstrated an
elevated ALC15 of 691 lymphocytes/mL (median; range, 281-
1785) compared with an ALC15 of 327 lymphocytes/mL
(median; range, 244-408) in the control patients (P < .04;
Figure 3A). We postulated that the infusion of the ex vivo
expanded cells with IL-2 administration would increase the
early recovery of NKG2DþCD3þCD8þ T cells in vivo. Figure 3B
demonstrates an increase in the number of circulating
NKG2DþCD3þCD8þ T cells at 15 days after transplantation,
compared with control patients (P < .02).
There was a signiﬁcant increase in the number of CD3þ
T cells (P < .0001), CD4þ T cells (P < .0009), and CD8þ T cells
(P< .007) in study patients, comparedwith the control group
(Figure 3C). There was also an increase in the IL-2 receptorFigure 3. Lymphocyte recovery on day 15 after transplantation. (A) Absolute lymp
lymphocytes circulating on day 15 after transplantation (ALC15). When compared to
increased (P < .04). The control group ¼ patients not treated on trial; the study gr
NKG2DþCD3þCD8þ T cells circulating in the study group (n ¼ 12) and the control grou
patients not treated on trial; the study group ¼ patients treated on trial. (C) Blood sam
patients from the control group (n ¼ 4) between days 21 and 28 after transplantation.
the 2 groups. When comparing cellular subsets between the 2 groups, there was a stat
CD8þ T cells (P < .007), and CD25þ cells (P < .009). The control group ¼ patients not tr
signiﬁcant results.expression (CD25) on circulating lymphocytes (P < .009).
There was no difference between the groups in the number
of circulating cytokine-induced killer cells, typically deﬁned
as CD8þCD56þ cells.
We were interested in 4 effector cell populations after
transplantation using this regimen. There was an increase
in the absolute number of circulating NKG2DþCD3þCD8þ
T cells/mL (P < .004), CD3þCD8þ T cells/mL (P < .04),
CD3þCD8þCD56þ T cells/mL (P < .004), and
NKG2DþCD3CD56þ T cells/mL (P < .003; Figure 4).Cytotoxicity: Evidence of Tumor-Speciﬁc Immunity
NKG2D ligand expression was examined on patients’
myeloma cells. Figure 5 demonstrates that patients’
myeloma cells strongly expressed 3 of the 6 NKG2D ligands
tested, including MICA, ULBP-1, and ULBP-3, when compared
to normal hematopoietic cells.hocyte numbers were calculated for each patient based on the number of
the control group (n ¼ 6), ALC15 in the study group (n ¼ 17) is signiﬁcantly
oup ¼ patients treated on trial. (B) Flow cytometry identiﬁed the number of
p (n ¼ 4) patients on day 15 after transplantation (P ¼ .02). The control group ¼
ples were obtained from patients treated on the trial (study group; n ¼ 7) and
Flow cytometric analyses identiﬁed cell populations circulating in the blood in
istically signiﬁcant increase in CD3þ T cells (P < .0001), CD4þ T cells (P < .0009),
eated on trial; the study group ¼ patients treated on trial. * Deﬁnes statistically
Figure 4. Circulating lymphocyte subsets in peripheral blood after transplantation. Phenotypic analyses identiﬁed the absolute number of NKG2DþCCD3þCD8þ (A),
CD3þCD8þ (B), CD3þCD8þCD56þ (C), and NKG2DþCD3-CD56þ cells/mL (D) in the study group (n ¼ 12) and in the control group (n ¼ 4) between days 21 and 28 after
transplantation. There was an increase in the absolute number of circulating NKG2DþCD3þCD8þ T cells (P < .004), CD3þCD8þ T cells (P < .04), CD3þCD8þCD56þ (P <
.004), and NKG2DþCD3-CD56þ cells (P < .003) when compared to circulating cells in the control group. * Deﬁnes statistically signiﬁcant results.
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was assessed using a human myeloma cell line (RPMI 8226)
as targets. Cytotoxicity of the circulating mononuclear cells
was markedly increased in the patients treated on trial
compared with control patients (Figure 6; P  .002).
Autologous myeloma cells were also used to examine
tumor-speciﬁc cytotoxicity. Patients’ mobilized peripheral
blood mononuclear cells (PBMCs) were isolated from study
patients (n ¼ 4) on the day of collection (“pre-expansion”)
and were expanded using the methods described above with
IL-2 and OKT3 for 7 days (“post-expansion”). Both pre-
expansion and post-expansion cells served as effector cells
in a cytotoxicity assay against autologous myeloma cells
(Figure 7). Autologous myeloma cell lysis was signiﬁcantly
increased after enrichment for NKG2DþCD3þCD8þ T cells
(P ¼ .02). Cytotoxicity was inhibited by NKG2D receptor
blocking (P < .001).
Response to Transplantation and Outcome Data
Of the 19 patients who underwent transplantation,
responses at 100 days after transplantation included CR (n ¼
12), VGPR (n¼ 5), PR (n¼ 1), and progressive disease (n¼ 1).
With a median follow-up of 25 months (range, 15-48
months), 17 patients are alive. Two patients have dieddue to progressive disease at 15 and 18 months after trans-
plantation. Of the 17 living patients, 8 patients remain
disease-free at 22 months after transplantation (median;
range, 16-42 months).
DISCUSSION
Despite transplantation’s success in improving survival in
patients with myeloma, the majority of patients relapse,
stressing the need for innovative therapies [25,26]. Our
previous laboratory and clinical results demonstrated that
a speciﬁc population of CD3þCD8þ T cells expressing an NK
cell activating receptor named NKG2D played a critical role in
killing autologous myeloma cells and could be a critical
lymphocyte population that contributes to improved
survival after transplantation [10,15,16,27]. The results of this
phase II trial demonstrate that this treatment is feasible and
safe, resulted in an increased absolute lymphocyte count on
day 15 after transplantation, and enhanced the number of
circulating NKG2DþCD3þCD8þ T cells. In addition, the
circulating mononuclear cells demonstrated enhanced
cytotoxicity against patients’ autologous myeloma cells [10].
We postulate that the increased number and function of the
NKG2DþCD3þCD8þ T cells may improve clinical outcomes by
eliminating residual myeloma cells in vivo. In contrast to our
Figure 5. NKG2D ligand expression in autologous myeloma cells. NKG2D ligand expression on autologous myeloma cells (n ¼ 5) or normal control marrows (n ¼ 3)
was measured by labeling cells with Abs directed against CD138, in combination with Abs directed against MICA, MICB, ULBP1, ULBP2, and ULBP3. The expression of
MICA (A), ULBP1 (B), and ULBP3 (C) is signiﬁcantly elevated on autologous myeloma cells (MM), when compared to controls (Control) (P < .0001 for each of the 3
ligands).
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addition of adoptive cellular therapy using cells enriched for
NKG2DþCD3þCD8þ T cells demonstrates tumor-speciﬁc
immunity, as demonstrated by the increased lysis of
autologous myeloma cells (Figure 7).
Although cytokine and adoptive cellular therapy are not
ﬁrmly established as treatment for myeloma, our clinical trial
results and our mouse experiments support the requirement
for NKG2DþCD3þCD8þ T cells to eradicate myeloma cells
in vivo [5,6,8,14-16,28-30]. The infusion of murine chimeric
NKG2DþCD3þCD8þ T cells in our myeloma-bearing mouse
model results in long-term survival and immunity against
the tumor [9,16-18,28,29,31-33].
NKG2D is an NK cell activating receptor that is present on
some CD8þ T cells, NK cells, and gdT cells. The NKG2D
receptor functions in association with an adaptor protein
called DAP10. After engagement with a ligand, NKG2D, in
complex with its adapter protein DAP10, activates PI3-kinase
with subsequent release of inﬂammatory cytokines and
cytolytic proteins causing target cell lysis [13,34]. Cell lysis
can be prevented by blocking NKG2D or by blocking one of its
ligands [10,14,34]. These ligands are present on most
malignant cells, includingmyeloma, but are not expressed on
normal tissue, except for MICA expression on gut epithelial
cells [12,35].
The NKG2D receptor model can be used for potential
therapeutic beneﬁts. The majority of tumors are sensitive toimmune responses that are triggered by the NKG2D acti-
vating receptor. Animal studies demonstrate that tumor cells
with minimal expression of NKG2D ligands tend to be more
resistant to therapy, suggesting the importance of NKG2D-
mediated recognition and tumor lysis [16,32,36]. Because
malignant cells may escape host recognition by down-
regulating MHC expression, NKG2DþCD3þCD8þ T cells
provide a unique advantage because they bypass the MHC-
restricted and TCR-dependent mechanisms [11].
The NKG2D receptor-ligand model can be manipulated
and used as a form of therapy. For example, a unique aspect
of this trial was the ability to use an ex vivo expansion
process to up-regulate the NKG2D receptor expression on
CD3þCD8þ T cells. These NKG2DþCD3þCD8þ T cells were
then used as adoptive cellular therapy. Another option is to
stimulate NKG2D ligand expression on tumor cells. IL-2 and
proteosome inhibitors up-regulate ligand expression on
malignant cells and enhance the NKG2D recognition of its
ligands [13,23,24,36,37]. Finally, posttransplantation cyto-
kine therapy will inﬂuence NKG2D expression on CD3þ
T cells. In this trial, the ex vivo expansion process and the
administration of IL-2 both up-regulate NKG2D expression
and NKG2D ligand expression on effector cells and their
targets, respectively.
Despite potential limitations associated with this
regimen, our laboratory results are encouraging. Although
we adhered to previously successful ex vivo expansion
Figure 6. Cytotoxicity after transplantation. Peripheral blood mononuclear
cells (PBMCs) were isolated from study group patients (n ¼ 5) and control
patients (n ¼ 4) between days 21 and 28 after transplantation. PBMCs were
used as effector cells in a 51Cr-release cytotoxicity assay against a myeloma cell
line (RPMI8226; E:T 100:1 for experimental and control groups). Myeloma cell
lysis was signiﬁcantly increased against RPMI cells in the study patients when
compared with control patients (P ¼ .002).
Figure 7. Cytotoxicity against autologous cells. Patients’ mobilized peripheral
blood mononuclear cells (PBMCs) were isolated from study group patients
(n ¼ 4) on the day of collection (“pre-expansion”) and were expanded ex vivo
using methods described within the article with IL-2 and OKT3 for 7 days
(“post-expansion”). Both pre-expansion and post-expansion cells served as
effector cells in a 51Cr-release cytotoxicity assay against autologous myeloma
cells (E:T 50:1). Myeloma cell lysis was signiﬁcantly increased against
autologous myeloma cells after enrichment for NKG2DþCD3þCD8þ T cells (P ¼
.02). Cytotoxicity was inhibited by NKG2D receptor blocking (P < .001) using
the same effectors and targets.
K.R. Meehan et al. / Biol Blood Marrow Transplant 19 (2013) 129e137136methods, the expansion of NKG2DþCD3þCD8þ T cells was
difﬁcult, and adequate expanded cell numbers could not be
achieved in some patients. Despite accruing 23 patients, only
15 patients received ex vivo 1/N expanded cells. These
difﬁculties were likely due to complexities with the ex vivo
expansion process, as well as difﬁculty in obtaining an
adequate number of cells from the leukocytophereses.
Although IL-2 may suppress hematopoiesis, our prior trials
using low-dose IL-2 immediately after transplantation did
not demonstrate this effect; yet the current patient numbers
within this trial are too small to address this question. Finally,
because a combination of IL-2 with adoptive cellular therapy
was used, we cannot identify if the IL-2 or the cellular infu-
sions demonstrated the greatest impact on the measure
parameters. In contrast to our previous trials using post-
transplantation IL-2 alone, the addition of adoptive cellular
therapy using cells enriched for NKG2DþCD3þCD8þ T cells
suggests enhanced tumor-speciﬁc immunity, as demon-
strated by the increased lysis of autologous myeloma cells.
Our ﬁndings introduce a novel method of enhancing
NKG2D expression on patients’ effector cells by using ex vivo
expansion of patients with myeloma-mobilized PBMCs.
Posttransplantation IL-2 and granulocyte macrophage
colony-stimulating factor offer the potential advantage of
stimulating the immune system while enhancing myeloma
cell NKG2D-ligand expression. We are continuing to evaluate
treatment regimens that increase NKG2D receptor expres-
sion on CD3þCD8þ T cells in vivo, while enhancing the
expression of NKG2D ligand expression on myeloma cells.
The clinical and laboratory results from this phase II trial
suggest a critical role for NKG2DþCD3þCD8þ T cells in thelysis of myeloma cells in the immediate posttransplantation
setting. Although the current clinical trial is closed, ongoing
analyses are evaluating the longevity of the in vivo circu-
lating NKG2DþCD3þCD8þ T cells. The results from these
studies will allow us to better understand cancer mecha-
nisms that could be used to treat many other malignancies,
because most malignant cells express targets recognized by
the NKG2DþCD3þCD8þ T cells.
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